Aadi Bioscience, Inc. (AADI)

Market Cap	304.74M
Revenue (ttm)	6.74M
Net Income (ttm)	-135.36M
Shares Out	21.02M
EPS (ttm)	-8.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,309
Open	14.27
Previous Close	13.99
Day's Range	14.10 - 14.60
52-Week Range	11.00 - 32.50
Beta	n/a
Analysts	Buy
Price Target	44.37 (+206.0%)
Earnings Date	Nov 8, 2022

About AADI

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

• Industry: Biotechnology
• Founded: 2011
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: AADI

Full Company Profile

Financial Performance

In 2021, AADI's revenue was $1.12 million, a decrease of -92.32% compared to the previous year's $14.58 million. Losses were -$110.09 million, 3,065.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AADI stock is "Buy." The 12-month stock price forecast is 44.37, which is an increase of 206.00% from the latest price.

Price Target

$44.37

(206.00% upside)

Analyst Consensus: Buy

Stock Forecasts